Mode
Text Size
Log in / Sign up

Diabetic Nephropathy

Part of Diabetes

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Diabetic Nephropathy

15 trials tracked for Diabetic Nephropathy: 9 in phase 3 or 4 and 4 with published results. The most-cited published study has 133 citations.

15Trials tracked
9Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 4 Phase 3 5 Phase 2 6
  1. Phase 4 Nephropathy In Type 2 Diabetes and Cardio-renal Events Completed · 133 cited
  2. Phase 3 Effect of Sulodexide in Early Diabetic Nephropathy Completed · 114 cited
  3. Phase 3 Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy Completed · 28 cited
  4. Phase 3 Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy Completed · 5 cited
  5. Phase 4 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy Completed
  6. Phase 4 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM) Completed
Show 9 more trials
  1. Phase 4 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes Completed
  2. Phase 3 ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial Completed
  3. Phase 3 Renoprotection in Early Diabetic Nephropathy in Pima Indians Completed
  4. Phase 2 The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors Completed
  5. Phase 2 Study of LY3016859 in Participants With Diabetic Nephropathy Completed
  6. Phase 2 A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy Completed
  7. Phase 2 Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy Completed
  8. Phase 2 Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients Completed
  9. Phase 2 N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Diabetic Nephropathy: what the trials found

Canagliflozin has demonstrated significant clinical benefits in patients with diabetic nephropathy. It significantly reduced the primary composite endpoint of doubling of serum creatinine, end-stage kidney disease, and renal or cardiovascular death (61.24% vs 43.21%, p<0.0001) 7. Additionally, Canagliflozin was associated with a significant reduction in the composite endpoint of cardiovascular death and hospitalized heart failure (45.44% vs 31.47%, p=0.0001) and a reduction in major adverse cardiac events (MACE) (48.67% vs 38.71%, p=0.0121) 7.

While Canagliflozin showed significant reductions in composite renal and cardiovascular outcomes, specific findings regarding eGFR decline were mixed; one trial reported no statistically significant difference in the change from baseline in eGFR at week 104 (p=0.351) 6. In other trials, standard of care was associated with a reduction in MACE compared to alternative treatments (146 vs 116, p<0.05) 1.

Other interventions investigated include sodium bicarbonate 2, Cyclosporin 3, Lipo-PGE1 4, Sulodexide 5, and Losartan 8. Olmesartan medoxomil showed no significant difference in renal composite outcomes (p=0.79) but did show a statistically significant reduction in cardiovascular composite outcomes (40 vs 53, p=0.039) 9.

Recent results — preliminary, needs further review

  • Nidufexor showed a ratio to baseline in urinary albumin to creatinine ratio (UACR) of 0.85-1.06 and stable eGFR ratios (0.94-0.98) 10.
  • PF-04634817 demonstrated a reduction from baseline in UACR at week 12 (13.27% vs 5.02%) 14.
  • Zemplar (paricalcitol) did not show statistically significant results for UACR reduction (p=0.071) or albumin levels (p=0.855) 15.

For the clinician treating this condition

  • Canagliflozin is supported by evidence for reducing primary composite renal endpoints and improving cardiovascular outcomes, including reduced heart failure hospitalizations and MACE.
  • Olmesartan medoxomil showed significant improvements in cardiovascular composite outcomes despite no significant difference in renal composite outcomes.
  • Standard of care was associated with a statistically significant reduction in major adverse cardiovascular events (MACE) compared to the alternative intervention studied.

AI synthesis of 12 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Diabetes

Related studies from across the Diabetes family.

AI-OCT reports reduced false-positive DME referral rates from 69.1% to 24.1%
Diabetes & Endocrinology RCT
AI-OCT reports reduced false-positive DME referral rates from 69.1% to 24.1% AI technology reduces unnecessary referrals for diabetic macular edema
This randomized clinical trial evaluated the impact of AI-OCT reports on identifying diabetic macular edema (DME) in patients with diabetes.…
New research shows that adding AI-powered imaging can significantly cut down on false alarms when screening patients for eye issues caused b…
Balanced crystalloids reduce time to DKA resolution by 1.60 hours compared to 0.9% saline
Pediatrics Meta-analysis
Balanced crystalloids reduce time to DKA resolution by 1.60 hours compared to 0.9% saline Balanced Crystalloids May Speed Recovery in Pediatric Diabetic Ketoacidosis
This meta-analysis of 320 pediatric patients with diabetic ketoacidosis found that balanced crystalloids significantly reduced the time to D…
A review of data suggests balanced crystalloid fluids may resolve diabetic ketoacidosis faster than standard saline in children.
Early subcutaneous basal insulin plus IV insulin reduces time to DKA resolution by 4.06 hours
Diabetes & Endocrinology Meta-analysis
Early subcutaneous basal insulin plus IV insulin reduces time to DKA resolution by 4.06 hours Early Subcutaneous Insulin Shortens Recovery Time for Diabetic Ketoacidosis
This meta-analysis of randomized controlled trials evaluated adding early subcutaneous basal insulin to intravenous insulin for adults with …
Adding early subcutaneous insulin to IV treatment can speed up recovery for patients with diabetic ketoacidosis without increasing safety ri…
Fluocinolone Acetonide Implant Shows Reduced Injection Frequency for Diabetic Macular Edema
Ophthalmology RCT
Fluocinolone Acetonide Implant Shows Reduced Injection Frequency for Diabetic Macular Edema Fluocinolone Acetonide Implant May Reduce Injection Frequency for DME
A Phase 4 trial shows fluocinolone acetonide implants achieve similar visual outcomes to aflibercept with significantly fewer total injectio…
A new eye implant for diabetic macular edema may significantly reduce the number of monthly injections needed to maintain vision.
High prevalence of microvascular and macrovascular complications among adult Ugandans with diabetes
Diabetes & Endocrinology Meta-analysis
High prevalence of microvascular and macrovascular complications among adult Ugandans with diabetes High rates of diabetes complications found in adult Ugandans
This meta-analysis examined the prevalence of various diabetic complications, including neuropathy and retinopathy, in a large cohort of adu…
More than half of Ugandan adults with diabetes suffer from nerve damage, highlighting a critical need for earlier screening and better care.
Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy
Neurology Sys. Review
Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy New research explores how inflammation drives nerve damage in diabetes
This narrative review explores the pathophysiology of diabetic peripheral neuropathy, focusing on how hyperglycemia, lipotoxicity, and intes…
Chronic high blood sugar causes more than just high glucose; it triggers a cycle of inflammation and immune stress that damages nerves.
Chronic hyperglycemia causes multi-level nerve damage across the peripheral, autonomic, and central nervous systems
Diabetes & Endocrinology Sys. Review
Chronic hyperglycemia causes multi-level nerve damage across the peripheral, autonomic, and central nervous systems Understanding how high blood sugar damages the entire nervous system in diabetes
This narrative review synthesizes how chronic hyperglycemia impacts the entire neuroaxis in patients with diabetes. It details metabolic and…
High blood sugar can damage nerves throughout the whole body. This affects your senses, movement, and internal organs.
Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in DME and RVO
Ophthalmology Meta-analysis
Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in DME and RVO Trial shows ziv-aflibercept improves vision in macular edema cases
This systematic review and meta-analysis of 5 RCTs and 8 observational studies found that intravitreal ziv-aflibercept significantly reduced…
A new eye treatment called ziv-aflibercept may help reduce swelling and improve vision for patients with specific types of macular edema.
Local antibiotic delivery systems increase healing rates in diabetic foot osteomyelitis compared with control groups in this meta-analysis
Infectious Disease Meta-analysis
Local antibiotic delivery systems increase healing rates in diabetic foot osteomyelitis compared with control groups in this meta-analysis Local Antibiotics May Boost Healing in Diabetic Foot Infections
This systematic review and meta-analysis evaluated local antibiotic delivery systems versus control groups for patients with diabetic foot o…
A new analysis suggests local antibiotic delivery may improve healing for diabetic foot bone infections, but more research is needed.
Antibiotic cement achieves 85.2% healing rate in diabetic foot osteomyelitis meta-analysis
Diabetes & Endocrinology Meta-analysis
Antibiotic cement achieves 85.2% healing rate in diabetic foot osteomyelitis meta-analysis Antibiotic cement may help heal diabetic foot infections without major surgery
A systematic review and meta-analysis of 82 patients with diabetic foot osteomyelitis found a weighted healing rate of 85.2% with antibiotic…
A meta-analysis suggests antibiotic-impregnated cement can heal diabetic foot osteomyelitis in most patients, though some still need surgery…
SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c
Diabetes & Endocrinology Meta-analysis
SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c New review shows SGLT2 drugs raise DKA risk when blood sugar is high
This meta-analysis of observational and randomized trials found SGLT2 inhibitor use is associated with an increased risk of diabetic ketoaci…
A big review of many studies found that medicines for diabetes called SGLT2 inhibitors can increase the chance of a serious condition called…
Perioperative anti-VEGF injections improve vision and reduce bleeding in proliferative diabetic retinopathy
Ophthalmology Meta-analysis
Perioperative anti-VEGF injections improve vision and reduce bleeding in proliferative diabetic retinopathy Anti-VEGF injections before eye surgery improve vision and reduce bleeding in diabetic retinopathy
This network meta-analysis evaluated the timing of perioperative anti-VEGF injections for proliferative diabetic retinopathy. Results indica…
A network meta-analysis of 2,646 eyes found that perioperative anti-VEGF injections improved vision and reduced bleeding in patients with pr…